Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

thrombocytopenia/protease

Link salvestatakse lõikelauale
8 tulemused

Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This protocol has been prepared by the Systemic Autoimmune Diseases Group (GEAS) steering committee from the Spanish Society of Internal Medicine (SEMI) in response to the current urgent situation that are living in Spain because of the COVID-19 pandemic. The GEAS member are experts in the treatment

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND Since the first case of Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) infection and its subsequent clinical manifestation (COronaVIrus Disease 19, COVID-19) in the city of Wuhan (Hubei, China) in December 2019, contagion abruptly spread to different regions of China

Prophylactic Anticoagulation for Catheter-related Thrombosis

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Study Type: Interventional, randomized, parallel Assignment and no masking Study Arms & Intervention: Drug 1: Aspirin, 100mg/day orally; Drug 2: rivaroxaban, 10mg/day orally; Drug 3: low molecule heparin, 4000IU(0.4ml)/day subcutaneous injection; Reference: mechanical prophylaxis. Follow-up Period:

HCV-HIV Co-infected Patient Cohort in Thailand

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Study Population Screening: HIV infected patients with a positive anti-HCV test will be approached for screening if they are at least 18 years old, participate in the PHPT cohort study, have evidence of control of HIV replication and have a CD4 cell count ≥200 cells/mm3 if currently receiving
Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is frequent because of shared modes of viral transmission. Near 20% of HIV-infected patients are also infected with HCV, the prevalence of HCV in the HIV population varying according to the route of transmission.

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Disease background: MM is a plasma cell tumor. It accounted for an estimated 20,180 new cases of cancer and 11,170 deaths in the United States in 2010. With a prevalence of 23 per 100,000 people, MM is an orphan disease (prevalence <5:10,000). The median age at diagnosis is 60-65 years. Although MM

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Despite cisplatin chemoradiation, 40-50% of women with locally advanced cervical cancer will die from their disease. The evaluation of new chemoradiation regimens have since included cisplatin to further build on its current success. In one year, Nelfinavir will be off patent and become a potential

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In murine and human xenograft tumor models, administration of PS-341 weekly was associated with significant antitumor activity. In primate studies using a schedule of twice weekly for six weeks, the highest PS-341 dose not associated with severe irreversible toxicity was 0.067 mg/kg/dose or 0.80
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge